Kyntra Bio Stock Up 3.9% on Trial

Overview

Kyntra Bio (NASDAQ:KYNB) shares increased 3.9% in after‑hours trading on Thursday after the company presented new data on roxadustat at the European Hematology Association Congress 2026 in Stockholm, Sweden.

Clinical Findings

The data stem from a post‑hoc analysis of the Phase 3 MATTERHORN trial in lower‑risk myelodysplastic syndromes (LR‑MDS) patients. Overall, 48% of patients receiving roxadustat achieved transfusion independence compared with 33% on placebo. In the ring sideroblast‑negative (RS‑) subgroup, which comprised 84 of the 140 enrolled patients, 48% of roxadustat‑treated patients attained at least eight weeks of transfusion independence over a 28‑week period versus 28% for placebo. Among patients with a high transfusion burden (defined as ≥4 units of packed red blood cells per 8‑week period for two consecutive 8‑week periods), roxadustat produced higher rates of eight‑, twelve‑, and sixteen‑week transfusion independence than placebo. Treatment‑emergent adverse events were generally lower grade, medically managed, and no new safety signals were identified.

Development Plan

Kyntra Bio indicated it is finalising the protocol for a pivotal Phase 3 trial of roxadustat for anemia in LR‑MDS patients with high transfusion burden, incorporating feedback from the U.S. Food and Drug Administration. The company expects to initiate this pivotal trial in the second half of 2026.